×
Supernus Pharmaceuticals Receivables 2011-2024 | SUPN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Supernus Pharmaceuticals receivables from 2011 to 2024. Receivables can be defined as the total amount of collectibles for a company
View More
Supernus Pharmaceuticals Receivables 2011-2024 | SUPN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Supernus Pharmaceuticals receivables from 2011 to 2024. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company Name
Market
Cap
Teva Pharmaceutical Industries (TEVA)
$20.1B
Dr Reddy's Laboratories (RDY)
$13.1B
BridgeBio Pharma (BBIO)
$5B
Bausch Health Cos (BHC)
$3B
Amphastar Pharmaceuticals (AMPH)
$2.4B
Taysha Gene Therapies (TSHA)
$449M
Personalis (PSNL)
$315M
Assembly Biosciences (ASMB)
$117M
Acasti Pharma (ACST)
$28M
Sol-Gel Technologies (SLGL)
$20M
Evoke Pharma (EVOK)
$4M
Teligent (TLGT)
$0M